Citarinostat(ACY-241) , 10mMinDMSO , 1316215-12-9
CAS NO.：1316215-12-9
Empirical Formula: C24H26ClN5O3
Molecular Weight: 467.95
MDL number: MFCD28023593
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB559.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Density | 1.293±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | ≥23.4 mg/mL in DMSO; insoluble in H2O; ≥4.87 mg/mL in EtOH with ultrasonic |
| form | solid |
| pka | 9.47±0.20(Predicted) |
| color | White to off-white |
Description and Uses
ACY-241 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 2.6 nM). It is selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all). It reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells when used at a concentration of 3 μM and completely inhibits it and induces apoptosis at a concentration of 10 μM. ACY-241, when used in combination with paclitaxel , inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells. It also reduces tumor growth in a MiaPaCa-2 mouse xenograft model when administered at a dose of 50 mg/kg in combination with paclitaxel. ACY-241, in combination with the somatostatin receptor agonist pasireotide , reduces hepatorenal cystogenesis in a rat model of polycystic liver disease.
Citarinostat is a HDAC inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 |
